Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Leases (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Leases data on record, last reported at $10.1 million in Q4 2025.

  • For Q4 2025, Leases rose 1726.09% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 1726.09%, while the annual FY2025 figure was $10.1 million, 1726.09% up from the prior year.
  • Leases reached $10.1 million in Q4 2025 per TARS's latest filing, down from $10.2 million in the prior quarter.
  • Across five years, Leases topped out at $10.2 million in Q3 2025 and bottomed at $229000.0 in Q2 2025.
  • Average Leases over 5 years is $2.0 million, with a median of $1.0 million recorded in 2021.
  • The widest YoY moves for Leases: up 1726.09% in 2025, down 88.37% in 2025.
  • A 5-year view of Leases shows it stood at $1.1 million in 2021, then crashed by 46.46% to $575000.0 in 2022, then soared by 226.96% to $1.9 million in 2023, then tumbled by 70.64% to $552000.0 in 2024, then surged by 1726.09% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $10.1 million in Q4 2025, $10.2 million in Q3 2025, and $229000.0 in Q2 2025.